Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has been granted a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its active pharmaceutical ingredient (API), Octreotide.
Octreotide is a synthetic peptide produced by Shilpa Pharma Lifesciences using solid-phase synthesis. It is used to treat various medical conditions, including acromegaly, severe diarrhea, and flushing episodes linked to metastatic carcinoid tumors, as well as profuse watery diarrhea associated with vasoactive intestinal peptide (VIP) secreting tumors.
This marks the second peptide molecule in Shilpa’s expanding peptide portfolio. The CEP granted by EDQM highlights the company’s ability to produce high-quality APIs that meet stringent global standards.
